

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vigonvita Life Sciences Co., Ltd.

蘇州旺山旺水生物醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2630)

INSIDE INFORMATION

COMPLETION OF H SHARE FULL CIRCULATION

This announcement is made by Vigonvita Life Sciences Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated November 27, 2025, June 29, 2026 and July 6, 2026 (the “**Announcements**”) in relation to the proposed implementation of the H Share Full Circulation by the Company, the issuance of Filing Notice by the CSRC for the H Share Full Circulation Application of the Company and grant of listing approval by the Stock Exchange in respect of the H Share Full Circulation of the Company. Unless otherwise stated, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board is pleased to announce that the conversion of 100,220,667 domestic Unlisted Shares into H Shares was completed on July 15, 2026, and the listing of the 100,220,667 converted H Shares on the Stock Exchange will commence at 9:00 a.m. on July 16, 2026. The Participating Shareholders may conduct trading of the converted H Shares subject to the completion of the applicable onshore arrangement procedures.

SHAREHOLDING STRUCTURE

The shareholding structure of the Company immediately before and upon the completion of the Conversion and Listing is as follows:

Type of Shares	Immediately before completion of the Conversion and Listing		Immediately upon completion of the Conversion and Listing	
	Number of Shares (Shares)	Approximate percentage of the total number of issued Shares of the Company	Number of Shares (Shares)	Approximate percentage of the total number of issued Shares of the Company
Domestic Unlisted Shares	100,920,667	60.22%	700,000	0.42%
H Shares	66,677,133	39.78%	166,897,800	99.58%
Total	167,597,800	100%	167,597,800	100%

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares of the Company.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, July 15, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.